| pubmed-article:16652422 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C0002062 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C0040300 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C0039082 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C1261381 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C0055082 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:16652422 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:16652422 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16652422 | pubmed:dateCreated | 2006-5-2 | lld:pubmed |
| pubmed-article:16652422 | pubmed:abstractText | Our previous study suggested that suppression by cepharanthin of tumor necrosis factor-a (TNF-a)-induced matrix metalloproteinase-9 (MMP-9) could prevent destruction of the acinar structure in the salivary glands of patients with Sjögren's syndrome (SS). In this study, we observed that in vivo administration of cepharanthin prevented severe damage to acinar tissues in the murine model of human SS. | lld:pubmed |
| pubmed-article:16652422 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16652422 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652422 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16652422 | pubmed:month | May | lld:pubmed |
| pubmed-article:16652422 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:SatoMitsunobu... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:AzumaMasayuki... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:TamataniTetsu... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:AshidaYukiY | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:HayashiYoshio... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:IshimaruNaozu... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:MotegiKatsumi... | lld:pubmed |
| pubmed-article:16652422 | pubmed:author | pubmed-author:TakamaruNatsu... | lld:pubmed |
| pubmed-article:16652422 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16652422 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:16652422 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16652422 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16652422 | pubmed:pagination | 912-20 | lld:pubmed |
| pubmed-article:16652422 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:meshHeading | pubmed-meshheading:16652422... | lld:pubmed |
| pubmed-article:16652422 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16652422 | pubmed:articleTitle | Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome. | lld:pubmed |
| pubmed-article:16652422 | pubmed:affiliation | Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan. azumasa@dent.tokushima-u.ac.jp | lld:pubmed |
| pubmed-article:16652422 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16652422 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
